Is LDN The Missing Link?

Happy Friday!

I just dropped a new video walking through low dose naltrexone.

Here are the links:

Watch on YouTube: https://youtu.be/Mwdkk6LpkM0

Listen on Spotify: https://open.spotify.com/episode/6FMsNiSgNUCMizAsX9tHR1?si=XhpDdYx-Qym_QKNz1M85Ug

The reason I keep coming back to LDN is simple.

Most people in the optimization world are stacking peptides and chasing hormones.

Almost nobody is talking about the molecule that quietly makes everything else work better.

Let’s dig in!

LDN History

Naltrexone got FDA approval in 1984 at 50mg for opioid addiction. At that dose, it fully blocks opioid receptors for 24 hours.

Then, in 1985, a Harvard-trained neurologist named Dr. Bernard Bihari noticed something strange.

His HIV and AIDS patients had less than 20% of normal endorphin levels. He wondered what would happen if he used a much smaller dose.

So he tested 1 mg up to 4.5 mg at bedtime. The blockade only lasted 3 to 6 hours. Then the body compensated by surging endorphin production by 200-300%.

That is the magic of LDN. You block briefly, the body overcompensates, and you ride that endorphin wave for the rest of the day.

In his 1985-86 placebo-controlled HIV trial, only 8% of patients on LDN died. In the placebo group, it was 33%. Small trial, but a massive effect size.

Bihari treated thousands of patients with autoimmune disease, cancer, and chronic pain before he passed in 2010.

The Mechanisms

LDN works on four pathways simultaneously.

One. The endorphin rebound. Bedtime blockade triggers a compensatory surge in beta-endorphin and met-enkephalin. Receptor density and sensitivity also increase. More endorphins hit more sensitive receptors all day.

Two. The OGF and OGFr axis. Drs. Ian Zagon and Patricia McLaughlin at Penn State spent 35 years on this. Met-enkephalin binds to OGFr, which upregulates p16 and p21. This slows cell replication at the G1/S checkpoint. Anti-proliferative without being cytotoxic.

Three. TLR4 antagonism. In 2008, researchers showed naltrexone directly blocks toll-like receptor 4 on microglia and macrophages. This is independent of the opioid system. It shifts microglia from a pro-inflammatory M1 to an anti-inflammatory M2 phenotype. Massive for chronic pain and neuroinflammation.

Four. Broad anti-inflammatory signaling. In 2017, Parkitny and Younger showed that eight weeks of LDN reduced 17 pro-inflammatory cytokines in fibromyalgia patients. T-regs go up. The HPA axis normalizes. The immune system stops screaming at everything.

This is why I call LDN a force multiplier. Most molecules do one thing well. LDN quietly does four.

Where LDN Shines

For Hashimoto's, around 40% of patients see meaningful improvement with antibody reductions.

For chronic pain, the Stanford fibromyalgia trial showed 28.8% pain reduction versus 18% on placebo.

For Crohn's, Dr. Jill Smith's NIH-funded RCT showed 78% endoscopic response versus 28% on placebo. Not just symptom relief, but actual mucosal healing on colonoscopy.

For depression, a Harvard randomized trial showed a large effect size in treatment-resistant cases.

For PCOS and infertility, naltrexone normalized cycles in 49 of 66 women with hypothalamic ovarian failure, and 18 got pregnant.

For acne and inflammatory skin conditions, the response is honestly pretty wild.

I struggled with acne as a kid and into adulthood. LDN was one of the closest things I have ever found to a real fix. Not perfect, but a major reduction.

Dosing

Most people start at 1.5 mg for 1 to 4 weeks, then move to 3 mg for another 1 to 4 weeks, then up to 4.5 mg if tolerated.

For me, 3 mg is the sweet spot. 4.5 is a little too stimulating at night. Some people do better with morning dosing if night dosing keeps them up, but most people sleep great on it.

About 37% of users get vivid dreams in the first couple of weeks. Mild headaches and nausea are possible and usually resolve within two weeks. A 2019 meta-analysis confirmed that there was no excess of adverse events versus placebo.

Always use immediate release. Never slow release. The whole mechanism depends on the brief blockade and clearance.

The one hard contraindication is concurrent sustained-release opioid use. You need a 7 to 10-day washout before starting LDN.

You also need at least 1 to 3 months at the target dose to know if it is working. Do not bail at four weeks.

LDN with HRT

This is the part nobody talks about, and it's why I think every person on TRT should at least consider LDN.

Chronic inflammation disrupts hormone receptor sensitivity. It can drive SHBG up. It can increase aromatase activity in guys with visceral fat. It can also impair thyroid conversion.

LDN lowers IL-6, TNF-alpha, IL-1beta, and a long list of other inflammatory markers. That clears the road for your hormones to actually do their job.

A lot of folks feel suboptimal on TRT even when their numbers look great on paper. Inflammation is often the bottleneck nobody is checking for.

For Hashimoto's, LDN directly addresses the autoimmune component.

For PCOS, it normalizes LH and FSH levels, lowers cortisol levels, and improves insulin sensitivity.

Women actually show a stronger HPA axis response to naltrexone than men, especially during high estrogen phases.

For sexual function, one small study showed that 11 of 15 men with idiopathic impotence had improved erectile function on LDN. The hormones did not change, but the endorphin signaling did.

I have been using TRT for years. LDN noticeably tightens up the parts of HRT that hormones alone cannot fix.

LDN with Peptides

This is where it gets really interesting.

LDN's TLR4 antagonism quiets the overactive innate immune response that drives injection-site inflammation and mast cell flare-ups.

It increases T-reg cells, which lowers the risk of developing anti-drug antibodies to your peptides. In principle, it can extend how long a peptide stays effective before you build up tolerance.

I would not start LDN just to chase that effect. But it is a real benefit on top of everything else.

A few specific pairings I like:

LDN and BPC-157. Both improve gut barrier function through complementary pathways. Great for IBD and gut healing.

LDN and TB-500. TB-500 drives cellular repair and angiogenesis. LDN handles the inflammation that is keeping the area from healing in the first place.

LDN and KPV. Direct mechanism overlap via NF-kappa B inhibition. LDN may also raise endogenous alpha-MSH, which is the parent molecule from which KPV is derived.

LDN and GLP-1s. This is the one I want to highlight. I have noticed I can stay at a much lower GLP-1 dose for much longer when I run LDN alongside it. Where most people lose appetite suppression at 2 mg of tirzepatide after 4 to 8 weeks, LDN can stretch that window to 12 to 16 weeks. Lower dose, fewer side effects, longer runway.

LDN and TA1. The most immunologically logical pairing for autoimmune conditions. TA1 stimulates CD4+ differentiation. LDN shifts the TH1/TH2 balance. Both reduce TNF alpha and IL-6.

LDN and SS-31. SS-31 targets mitochondrial function. LDN reduces the cytokine burden that damages mitochondria in the first place. Two non-overlapping pathways. Great combo for chronic fatigue, long COVID, and aging.

Final Thoughts

For years, I went 3 months on, 3 months off. I felt fine off it. I just felt better on it.

Over the last 8 months, I have run it continuously at 3 mg every night and noticed only benefits. I plan to do a full year and then come off briefly to compare.

If you are new to LDN, I would still recommend starting with the 3-on, 3-off approach. See how you feel. Adjust from there.

The whole point of LDN is that it improves everything else in your protocol. Lower inflammation. Cleaner immune signaling. More endorphin tone. Less neuroinflammation.

Sometimes, that is the last 5 to 10% most people are missing.

Have a fantastic weekend!

Best, Hunter

P.S. I get my LDN from Agelessrx.com. It’s very cheap and easy to get a prescription for.

Further reading